apollomicsinc
Foster City, CA, and Hangzhou, China, Jan 4, 2022 - (ACN Newswire) - Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer of Apollomics, was recently appointed to Chairman of the Board for the BayHelix Group, effective January 2022. "I am honored to be selected by my peers to help guide the BayHelix Group as it continues to foster biotech innovations and expand business opportunities within the broad life sciences ...
ACN Newswire
Foster City, CA, Shanghai and Hangzhou, China, Nov 22, 2021 - (ACN Newswire) - Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully dosed in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) in China. Apollomics licensed the Greater China rights for uproleselan from GlycoMimetics. "As our first Phase 3 clinical trial, dosing of the first patient wit...
ACN Newswire
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら